SYHA1813
Phase 2Small molecule
SYHA1813 is one of 33 small molecule programs targeting Meningioma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Locally Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Stivarga
BayerPhase 2
Afinitor
NovartisPhase 2
OPDUALAG
Bristol-Myers SquibbPhase 2
Budigalimab
AbbViePhase 1
BL-M08D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
SYHA1813
SShanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 2
BC3195
BBiocity Biopharmaceutics Co., Ltd.
Phase 2
ASKB589
AAskGene Pharma, Inc.
Phase 2
KB707
KKrystal Biotech, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic Solid Tumors1 trial
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled
Meningioma1 trial
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 2·NCT06739213·56 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYHA1813. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details